Liu Feng, Zhang Chun Qing, Wang Guang Chuan, Liu Fu Li, Xu Hong Wei, Xu Lin, Feng Kai
Department of Gastroenterology, Provincial Hospital Affiliated to Shandong University, Jinan, China 250021.
Gastroenterology Res. 2009 Oct;2(5):289-294. doi: 10.4021/gr2009.10.1315. Epub 2009 Sep 20.
To summarize the experiences with the technique of percutaneous biliary stent placement for treatment of malignant biliary obstruction in patients with different types of biliary obstruction.
Percutaneous biliary stent placement was performed in 126 patients with malignant biliary obstruction. The etiology included 56 cases of cholangiocarcinoma, 28 cases of pancreatic cancer, 12 cases of ampullary carcinoma, 10 cases of primary hepatic carcinoma, 8 cases of gastric cancer metastasis, 6 cases of gallbladder carcinoma, and 6 cases of liver metastasis of colon cancer. The obstructed lesion predominantly involved the common bile duct in 42 patients, common hepatic duct in 39 patients, and hilar bile duct in 45 patients. When the bile duct was punctured successfully under fluoroscopy, the guide wire was explored to across the obstruction segment under the assistant of catheter, then the stent was inserted along the super-slippery guide wire. In patients with hilar hepatic duct lesions involving both left and right hepatic ducts, the both ducts were punctured and bilateral stenting was performed. A 8.5 F internal/external drainage catheter was inserted. The liver function test and ultrasound were performed one week after the procedure to observe the decrease of bilirubin and alleviation of biliary obstruction.
A total of 166 stents were implanted in 126 patients. In the 42 patients with common bile duct obstruction, each patient was implanted one stent. In the 39 patients with common hepatic duct obstruction, each patient was impanted one stent. In the 45 patients with hilur bile duct obstruction, 38 patients were placed 2 stents, one patient was placed with 3 stents, and the rest were placed with one stent. The serum total bilirubin decreased from 309.2 ± 158.3 µmol/L before the procedure to148.5 ± 98.0 µmol/L one week after the procedure (P < 0.001). Alkaline phosphatase and alanine aminotransferase significantly decreased (P < 0.001). Five cases died within 1 month (4%) after the procedure. Complications occurred in 9 cases (7.1%). Six patients underwent combined duodenal self-expandable metal stent placement successfully.
The percutaneous biliary stent placement is a safe and effective palliative therapy for malignant biliary obstruction by improving liver function and 1ife quality.
总结经皮胆道支架置入术治疗不同类型胆道梗阻患者恶性胆道梗阻的经验。
对126例恶性胆道梗阻患者行经皮胆道支架置入术。病因包括胆管癌56例、胰腺癌28例、壶腹癌12例、原发性肝癌10例、胃癌转移8例、胆囊癌6例、结肠癌肝转移6例。梗阻病变主要累及胆总管42例、肝总管39例、肝门部胆管45例。在透视下成功穿刺胆管后,在导管辅助下将导丝探过梗阻段,然后沿超滑导丝置入支架。对于累及左右肝管的肝门部肝管病变患者,对双侧胆管进行穿刺并置入双侧支架。插入一根8.5F的内外引流导管。术后1周进行肝功能检查和超声检查,观察胆红素下降及胆道梗阻缓解情况。
126例患者共置入166枚支架。42例胆总管梗阻患者,每例置入1枚支架。39例肝总管梗阻患者,每例置入1枚支架。45例肝门部胆管梗阻患者中,38例置入2枚支架,1例置入3枚支架,其余置入1枚支架。血清总胆红素由术前的309.2±158.3µmol/L降至术后1周的148.5±98.0µmol/L(P<0.001)。碱性磷酸酶和谷丙转氨酶显著下降(P<0.001)。5例患者术后1个月内死亡(4%)。9例(7.1%)发生并发症。6例患者成功接受了十二指肠自膨式金属支架置入术。
经皮胆道支架置入术是一种通过改善肝功能和生活质量治疗恶性胆道梗阻的安全有效的姑息治疗方法。